Syra Health Corp. Class A Common Stock
Syra Health Corp. Class A Common Stock SYRA Peers
See (SYRA) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SYRA | $0.10 | +25.00% | 1.19M | -0.20 | -$0.50 | N/A |
| HCA | $363.35 | +2.73% | 87.41B | 16.13 | $22.53 | +0.74% |
| FMS | $28.12 | -0.95% | 16.50B | 23.63 | $1.19 | +2.26% |
| THC | $154.57 | +3.86% | 14.36B | 9.91 | $15.60 | N/A |
| SOLV | $74.78 | +6.48% | 12.94B | 27.09 | $2.76 | N/A |
| UHS | $191.56 | +5.38% | 12.34B | 10.76 | $17.80 | +0.42% |
| EHC | $116.93 | +0.45% | 11.79B | 24.06 | $4.86 | +0.56% |
| DVA | $144.08 | +0.22% | 11.07B | 13.43 | $10.73 | N/A |
| OSH | $39.00 | +0.08% | 9.52B | -17.65 | -$2.21 | N/A |
| CHE | $569.35 | -0.15% | 8.33B | 27.77 | $20.50 | +0.33% |
Stock Comparison
SYRA vs HCA Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, HCA has a market cap of 87.41B. Regarding current trading prices, SYRA is priced at $0.10, while HCA trades at $363.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas HCA's P/E ratio is 16.13. In terms of profitability, SYRA's ROE is -1.28%, compared to HCA's ROE of -2.36%. Regarding short-term risk, SYRA is more volatile compared to HCA. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs FMS Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, FMS has a market cap of 16.50B. Regarding current trading prices, SYRA is priced at $0.10, while FMS trades at $28.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas FMS's P/E ratio is 23.63. In terms of profitability, SYRA's ROE is -1.28%, compared to FMS's ROE of +0.04%. Regarding short-term risk, SYRA is more volatile compared to FMS. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs THC Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, THC has a market cap of 14.36B. Regarding current trading prices, SYRA is priced at $0.10, while THC trades at $154.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas THC's P/E ratio is 9.91. In terms of profitability, SYRA's ROE is -1.28%, compared to THC's ROE of +0.37%. Regarding short-term risk, SYRA is more volatile compared to THC. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs SOLV Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, SOLV has a market cap of 12.94B. Regarding current trading prices, SYRA is priced at $0.10, while SOLV trades at $74.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas SOLV's P/E ratio is 27.09. In terms of profitability, SYRA's ROE is -1.28%, compared to SOLV's ROE of +0.15%. Regarding short-term risk, SYRA is more volatile compared to SOLV. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs UHS Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, UHS has a market cap of 12.34B. Regarding current trading prices, SYRA is priced at $0.10, while UHS trades at $191.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas UHS's P/E ratio is 10.76. In terms of profitability, SYRA's ROE is -1.28%, compared to UHS's ROE of +0.18%. Regarding short-term risk, SYRA is more volatile compared to UHS. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs EHC Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, EHC has a market cap of 11.79B. Regarding current trading prices, SYRA is priced at $0.10, while EHC trades at $116.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas EHC's P/E ratio is 24.06. In terms of profitability, SYRA's ROE is -1.28%, compared to EHC's ROE of +0.25%. Regarding short-term risk, SYRA is more volatile compared to EHC. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs DVA Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, DVA has a market cap of 11.07B. Regarding current trading prices, SYRA is priced at $0.10, while DVA trades at $144.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas DVA's P/E ratio is 13.43. In terms of profitability, SYRA's ROE is -1.28%, compared to DVA's ROE of +1.81%. Regarding short-term risk, SYRA is more volatile compared to DVA. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs OSH Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, OSH has a market cap of 9.52B. Regarding current trading prices, SYRA is priced at $0.10, while OSH trades at $39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas OSH's P/E ratio is -17.65. In terms of profitability, SYRA's ROE is -1.28%, compared to OSH's ROE of +4.64%. Regarding short-term risk, SYRA is more volatile compared to OSH. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs CHE Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, CHE has a market cap of 8.33B. Regarding current trading prices, SYRA is priced at $0.10, while CHE trades at $569.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas CHE's P/E ratio is 27.77. In terms of profitability, SYRA's ROE is -1.28%, compared to CHE's ROE of +0.26%. Regarding short-term risk, SYRA is more volatile compared to CHE. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs ENSG Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, ENSG has a market cap of 8.14B. Regarding current trading prices, SYRA is priced at $0.10, while ENSG trades at $141.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas ENSG's P/E ratio is 26.71. In terms of profitability, SYRA's ROE is -1.28%, compared to ENSG's ROE of +0.17%. Regarding short-term risk, SYRA is more volatile compared to ENSG. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs LHCG Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, LHCG has a market cap of 5.29B. Regarding current trading prices, SYRA is priced at $0.10, while LHCG trades at $169.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas LHCG's P/E ratio is 82.83. In terms of profitability, SYRA's ROE is -1.28%, compared to LHCG's ROE of +0.04%. Regarding short-term risk, SYRA is more volatile compared to LHCG. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs OPCH Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, OPCH has a market cap of 5.22B. Regarding current trading prices, SYRA is priced at $0.10, while OPCH trades at $31.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas OPCH's P/E ratio is 25.49. In terms of profitability, SYRA's ROE is -1.28%, compared to OPCH's ROE of +0.15%. Regarding short-term risk, SYRA is more volatile compared to OPCH. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs AMED Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, AMED has a market cap of 3.13B. Regarding current trading prices, SYRA is priced at $0.10, while AMED trades at $95.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas AMED's P/E ratio is 35.21. In terms of profitability, SYRA's ROE is -1.28%, compared to AMED's ROE of +0.10%. Regarding short-term risk, SYRA is more volatile compared to AMED. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs SGRY Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, SGRY has a market cap of 3.05B. Regarding current trading prices, SYRA is priced at $0.10, while SGRY trades at $23.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas SGRY's P/E ratio is -18.02. In terms of profitability, SYRA's ROE is -1.28%, compared to SGRY's ROE of -0.09%. Regarding short-term risk, SYRA is more volatile compared to SGRY. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs ACHC Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, ACHC has a market cap of 2.38B. Regarding current trading prices, SYRA is priced at $0.10, while ACHC trades at $25.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas ACHC's P/E ratio is 9.29. In terms of profitability, SYRA's ROE is -1.28%, compared to ACHC's ROE of +0.09%. Regarding short-term risk, SYRA is more volatile compared to ACHC. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs LFST Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, LFST has a market cap of 2.27B. Regarding current trading prices, SYRA is priced at $0.10, while LFST trades at $5.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas LFST's P/E ratio is -65.00. In terms of profitability, SYRA's ROE is -1.28%, compared to LFST's ROE of -0.04%. Regarding short-term risk, SYRA is more volatile compared to LFST. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs ARDT Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, ARDT has a market cap of 2.12B. Regarding current trading prices, SYRA is priced at $0.10, while ARDT trades at $14.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas ARDT's P/E ratio is 8.84. In terms of profitability, SYRA's ROE is -1.28%, compared to ARDT's ROE of +0.30%. Regarding short-term risk, SYRA is more volatile compared to ARDT. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs ADUS Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, ADUS has a market cap of 2.03B. Regarding current trading prices, SYRA is priced at $0.10, while ADUS trades at $110.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas ADUS's P/E ratio is 25.01. In terms of profitability, SYRA's ROE is -1.28%, compared to ADUS's ROE of +0.08%. Regarding short-term risk, SYRA is more volatile compared to ADUS. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs SEM Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, SEM has a market cap of 1.96B. Regarding current trading prices, SYRA is priced at $0.10, while SEM trades at $15.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas SEM's P/E ratio is 24.60. In terms of profitability, SYRA's ROE is -1.28%, compared to SEM's ROE of +0.10%. Regarding short-term risk, SYRA is more volatile compared to SEM. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs AMEH Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, AMEH has a market cap of 1.83B. Regarding current trading prices, SYRA is priced at $0.10, while AMEH trades at $40.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas AMEH's P/E ratio is 39.25. In terms of profitability, SYRA's ROE is -1.28%, compared to AMEH's ROE of +0.06%. Regarding short-term risk, SYRA is more volatile compared to AMEH. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs BKD Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, BKD has a market cap of 1.60B. Regarding current trading prices, SYRA is priced at $0.10, while BKD trades at $6.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas BKD's P/E ratio is -6.58. In terms of profitability, SYRA's ROE is -1.28%, compared to BKD's ROE of -0.66%. Regarding short-term risk, SYRA is more volatile compared to BKD. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs ASTH Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, ASTH has a market cap of 1.60B. Regarding current trading prices, SYRA is priced at $0.10, while ASTH trades at $28.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas ASTH's P/E ratio is 31.71. In terms of profitability, SYRA's ROE is -1.28%, compared to ASTH's ROE of +0.06%. Regarding short-term risk, SYRA is more volatile compared to ASTH. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs NHC Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, NHC has a market cap of 1.59B. Regarding current trading prices, SYRA is priced at $0.10, while NHC trades at $102.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas NHC's P/E ratio is 15.73. In terms of profitability, SYRA's ROE is -1.28%, compared to NHC's ROE of +0.11%. Regarding short-term risk, SYRA is more volatile compared to NHC. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs MD Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, MD has a market cap of 1.23B. Regarding current trading prices, SYRA is priced at $0.10, while MD trades at $14.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas MD's P/E ratio is -14.36. In terms of profitability, SYRA's ROE is -1.28%, compared to MD's ROE of -0.13%. Regarding short-term risk, SYRA is more volatile compared to MD. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs BKDT Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, BKDT has a market cap of 1.23B. Regarding current trading prices, SYRA is priced at $0.10, while BKDT trades at $77.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas BKDT's P/E ratio is N/A. In terms of profitability, SYRA's ROE is -1.28%, compared to BKDT's ROE of -0.66%. Regarding short-term risk, SYRA is more volatile compared to BKDT. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs AGL Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, AGL has a market cap of 1.23B. Regarding current trading prices, SYRA is priced at $0.10, while AGL trades at $2.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas AGL's P/E ratio is -4.78. In terms of profitability, SYRA's ROE is -1.28%, compared to AGL's ROE of -0.42%. Regarding short-term risk, SYRA is more volatile compared to AGL. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs USPH Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, USPH has a market cap of 1.18B. Regarding current trading prices, SYRA is priced at $0.10, while USPH trades at $77.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas USPH's P/E ratio is 42.08. In terms of profitability, SYRA's ROE is -1.28%, compared to USPH's ROE of +0.05%. Regarding short-term risk, SYRA is more volatile compared to USPH. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs AVAH Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, AVAH has a market cap of 1.13B. Regarding current trading prices, SYRA is priced at $0.10, while AVAH trades at $5.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas AVAH's P/E ratio is -96.33. In terms of profitability, SYRA's ROE is -1.28%, compared to AVAH's ROE of +0.08%. Regarding short-term risk, SYRA is more volatile compared to AVAH. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs HCSG Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, HCSG has a market cap of 1.06B. Regarding current trading prices, SYRA is priced at $0.10, while HCSG trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas HCSG's P/E ratio is 26.35. In terms of profitability, SYRA's ROE is -1.28%, compared to HCSG's ROE of +0.08%. Regarding short-term risk, SYRA is more volatile compared to HCSG. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs PNTG Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, PNTG has a market cap of 1.02B. Regarding current trading prices, SYRA is priced at $0.10, while PNTG trades at $29.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas PNTG's P/E ratio is 42.21. In terms of profitability, SYRA's ROE is -1.28%, compared to PNTG's ROE of +0.12%. Regarding short-term risk, SYRA is more volatile compared to PNTG. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs AMN Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, AMN has a market cap of 865.25M. Regarding current trading prices, SYRA is priced at $0.10, while AMN trades at $22.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas AMN's P/E ratio is -5.88. In terms of profitability, SYRA's ROE is -1.28%, compared to AMN's ROE of -0.18%. Regarding short-term risk, SYRA is more volatile compared to AMN. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs CYH Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, CYH has a market cap of 543.69M. Regarding current trading prices, SYRA is priced at $0.10, while CYH trades at $3.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas CYH's P/E ratio is -1.05. In terms of profitability, SYRA's ROE is -1.28%, compared to CYH's ROE of +0.30%. Regarding short-term risk, SYRA is more volatile compared to CYH. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs EHAB Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, EHAB has a market cap of 528.65M. Regarding current trading prices, SYRA is priced at $0.10, while EHAB trades at $10.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas EHAB's P/E ratio is -3.36. In terms of profitability, SYRA's ROE is -1.28%, compared to EHAB's ROE of -0.26%. Regarding short-term risk, SYRA is more volatile compared to EHAB. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs TALK Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, TALK has a market cap of 515.49M. Regarding current trading prices, SYRA is priced at $0.10, while TALK trades at $3.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas TALK's P/E ratio is 308.00. In terms of profitability, SYRA's ROE is -1.28%, compared to TALK's ROE of -0.04%. Regarding short-term risk, SYRA is more volatile compared to TALK. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs INNV Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, INNV has a market cap of 513.05M. Regarding current trading prices, SYRA is priced at $0.10, while INNV trades at $3.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas INNV's P/E ratio is -20.00. In terms of profitability, SYRA's ROE is -1.28%, compared to INNV's ROE of -0.10%. Regarding short-term risk, SYRA is more volatile compared to INNV. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs AUNA Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, AUNA has a market cap of 511.69M. Regarding current trading prices, SYRA is priced at $0.10, while AUNA trades at $6.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas AUNA's P/E ratio is 15.71. In terms of profitability, SYRA's ROE is -1.28%, compared to AUNA's ROE of +0.07%. Regarding short-term risk, SYRA is more volatile compared to AUNA. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs SNDA Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, SNDA has a market cap of 510.48M. Regarding current trading prices, SYRA is priced at $0.10, while SNDA trades at $27.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas SNDA's P/E ratio is -50.11. In terms of profitability, SYRA's ROE is -1.28%, compared to SNDA's ROE of -0.03%. Regarding short-term risk, SYRA is more volatile compared to SNDA. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs TALKW Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, TALKW has a market cap of 478.37M. Regarding current trading prices, SYRA is priced at $0.10, while TALKW trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas TALKW's P/E ratio is N/A. In terms of profitability, SYRA's ROE is -1.28%, compared to TALKW's ROE of -0.04%. Regarding short-term risk, SYRA is more volatile compared to TALKW. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs CCRN Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, CCRN has a market cap of 456.34M. Regarding current trading prices, SYRA is priced at $0.10, while CCRN trades at $13.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas CCRN's P/E ratio is -31.64. In terms of profitability, SYRA's ROE is -1.28%, compared to CCRN's ROE of -0.03%. Regarding short-term risk, SYRA is more volatile compared to CCRN. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs CMPS Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, CMPS has a market cap of 363.04M. Regarding current trading prices, SYRA is priced at $0.10, while CMPS trades at $3.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas CMPS's P/E ratio is -1.70. In terms of profitability, SYRA's ROE is -1.28%, compared to CMPS's ROE of -0.74%. Regarding short-term risk, SYRA is more volatile compared to CMPS. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs CSU Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, CSU has a market cap of 223.71M. Regarding current trading prices, SYRA is priced at $0.10, while CSU trades at $33.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas CSU's P/E ratio is 0.67. In terms of profitability, SYRA's ROE is -1.28%, compared to CSU's ROE of +2.23%. Regarding short-term risk, SYRA is more volatile compared to CSU. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs BTMD Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, BTMD has a market cap of 218.29M. Regarding current trading prices, SYRA is priced at $0.10, while BTMD trades at $3.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas BTMD's P/E ratio is 44.33. In terms of profitability, SYRA's ROE is -1.28%, compared to BTMD's ROE of -0.06%. Regarding short-term risk, SYRA is more volatile compared to BTMD. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs AIRS Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, AIRS has a market cap of 194.56M. Regarding current trading prices, SYRA is priced at $0.10, while AIRS trades at $3.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas AIRS's P/E ratio is -11.41. In terms of profitability, SYRA's ROE is -1.28%, compared to AIRS's ROE of -0.21%. Regarding short-term risk, SYRA is more volatile compared to AIRS. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs TOI Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, TOI has a market cap of 193.17M. Regarding current trading prices, SYRA is priced at $0.10, while TOI trades at $2.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas TOI's P/E ratio is -3.59. In terms of profitability, SYRA's ROE is -1.28%, compared to TOI's ROE of -2.73%. Regarding short-term risk, SYRA is more volatile compared to TOI. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs AONC Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, AONC has a market cap of 175.50M. Regarding current trading prices, SYRA is priced at $0.10, while AONC trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas AONC's P/E ratio is -6.74. In terms of profitability, SYRA's ROE is -1.28%, compared to AONC's ROE of +0.25%. Regarding short-term risk, SYRA is more volatile compared to AONC. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs JYNT Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, JYNT has a market cap of 155.06M. Regarding current trading prices, SYRA is priced at $0.10, while JYNT trades at $10.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas JYNT's P/E ratio is -101.20. In terms of profitability, SYRA's ROE is -1.28%, compared to JYNT's ROE of -0.00%. Regarding short-term risk, SYRA is more volatile compared to JYNT. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs DCGO Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, DCGO has a market cap of 143.21M. Regarding current trading prices, SYRA is priced at $0.10, while DCGO trades at $1.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas DCGO's P/E ratio is 8.03. In terms of profitability, SYRA's ROE is -1.28%, compared to DCGO's ROE of +0.00%. Regarding short-term risk, SYRA is more volatile compared to DCGO. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs FVE Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, FVE has a market cap of 98.39M. Regarding current trading prices, SYRA is priced at $0.10, while FVE trades at $2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas FVE's P/E ratio is -5.64. In terms of profitability, SYRA's ROE is -1.28%, compared to FVE's ROE of -0.15%. Regarding short-term risk, SYRA is more volatile compared to FVE. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs PIIIW Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, PIIIW has a market cap of 67.53M. Regarding current trading prices, SYRA is priced at $0.10, while PIIIW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas PIIIW's P/E ratio is -0.01. In terms of profitability, SYRA's ROE is -1.28%, compared to PIIIW's ROE of -1.07%. Regarding short-term risk, SYRA is less volatile compared to PIIIW. This indicates potentially lower risk in terms of short-term price fluctuations for SYRA.
SYRA vs PIII Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, PIII has a market cap of 60.69M. Regarding current trading prices, SYRA is priced at $0.10, while PIII trades at $8.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas PIII's P/E ratio is -0.16. In terms of profitability, SYRA's ROE is -1.28%, compared to PIII's ROE of -1.07%. Regarding short-term risk, SYRA is more volatile compared to PIII. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs ALR Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, ALR has a market cap of 44.18M. Regarding current trading prices, SYRA is priced at $0.10, while ALR trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas ALR's P/E ratio is -1.11. In terms of profitability, SYRA's ROE is -1.28%, compared to ALR's ROE of -0.15%. Regarding short-term risk, SYRA is more volatile compared to ALR. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs KDLYW Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, KDLYW has a market cap of 40.97M. Regarding current trading prices, SYRA is priced at $0.10, while KDLYW trades at $7.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas KDLYW's P/E ratio is N/A. In terms of profitability, SYRA's ROE is -1.28%, compared to KDLYW's ROE of -1.44%. Regarding short-term risk, SYRA is less volatile compared to KDLYW. This indicates potentially lower risk in terms of short-term price fluctuations for SYRA.
SYRA vs CCEL Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, CCEL has a market cap of 40.57M. Regarding current trading prices, SYRA is priced at $0.10, while CCEL trades at $5.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas CCEL's P/E ratio is 502.00. In terms of profitability, SYRA's ROE is -1.28%, compared to CCEL's ROE of -0.01%. Regarding short-term risk, SYRA is more volatile compared to CCEL. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs IMAC Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, IMAC has a market cap of 33.08M. Regarding current trading prices, SYRA is priced at $0.10, while IMAC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas IMAC's P/E ratio is -2.27. In terms of profitability, SYRA's ROE is -1.28%, compared to IMAC's ROE of +2.46%. Regarding short-term risk, SYRA is more volatile compared to IMAC. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs AMS Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, AMS has a market cap of 18.19M. Regarding current trading prices, SYRA is priced at $0.10, while AMS trades at $2.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas AMS's P/E ratio is 8.55. In terms of profitability, SYRA's ROE is -1.28%, compared to AMS's ROE of +0.09%. Regarding short-term risk, SYRA is more volatile compared to AMS. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs MODV Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, MODV has a market cap of 17.79M. Regarding current trading prices, SYRA is priced at $0.10, while MODV trades at $1.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas MODV's P/E ratio is -0.09. In terms of profitability, SYRA's ROE is -1.28%, compared to MODV's ROE of -8.96%. Regarding short-term risk, SYRA is more volatile compared to MODV. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs AIH Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, AIH has a market cap of 15.93M. Regarding current trading prices, SYRA is priced at $0.10, while AIH trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas AIH's P/E ratio is -2.78. In terms of profitability, SYRA's ROE is -1.28%, compared to AIH's ROE of -0.79%. Regarding short-term risk, SYRA is less volatile compared to AIH. This indicates potentially lower risk in terms of short-term price fluctuations for SYRA.
SYRA vs CANO Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, CANO has a market cap of 12.43M. Regarding current trading prices, SYRA is priced at $0.10, while CANO trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas CANO's P/E ratio is -0.01. In terms of profitability, SYRA's ROE is -1.28%, compared to CANO's ROE of -32.61%. Regarding short-term risk, SYRA is more volatile compared to CANO. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs FTRP Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, FTRP has a market cap of 9.81M. Regarding current trading prices, SYRA is priced at $0.10, while FTRP trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas FTRP's P/E ratio is -1.22. In terms of profitability, SYRA's ROE is -1.28%, compared to FTRP's ROE of -0.62%. Regarding short-term risk, SYRA is more volatile compared to FTRP. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs MNDR Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, MNDR has a market cap of 6.09M. Regarding current trading prices, SYRA is priced at $0.10, while MNDR trades at $1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas MNDR's P/E ratio is -0.31. In terms of profitability, SYRA's ROE is -1.28%, compared to MNDR's ROE of -5.70%. Regarding short-term risk, SYRA is more volatile compared to MNDR. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs GBNH Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, GBNH has a market cap of 5.52M. Regarding current trading prices, SYRA is priced at $0.10, while GBNH trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas GBNH's P/E ratio is -0.06. In terms of profitability, SYRA's ROE is -1.28%, compared to GBNH's ROE of +0.51%. Regarding short-term risk, SYRA is less volatile compared to GBNH. This indicates potentially lower risk in terms of short-term price fluctuations for SYRA.
SYRA vs TOIIW Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, TOIIW has a market cap of 5.30M. Regarding current trading prices, SYRA is priced at $0.10, while TOIIW trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas TOIIW's P/E ratio is N/A. In terms of profitability, SYRA's ROE is -1.28%, compared to TOIIW's ROE of -2.73%. Regarding short-term risk, SYRA is more volatile compared to TOIIW. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs RHE Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, RHE has a market cap of 5.21M. Regarding current trading prices, SYRA is priced at $0.10, while RHE trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas RHE's P/E ratio is -1.79. In terms of profitability, SYRA's ROE is -1.28%, compared to RHE's ROE of +2.66%. Regarding short-term risk, SYRA is more volatile compared to RHE. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs ATIP Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, ATIP has a market cap of 3.66M. Regarding current trading prices, SYRA is priced at $0.10, while ATIP trades at $0.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas ATIP's P/E ratio is -0.04. In terms of profitability, SYRA's ROE is -1.28%, compared to ATIP's ROE of +1.77%. Regarding short-term risk, SYRA is more volatile compared to ATIP. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs IMACW Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, IMACW has a market cap of 1.74M. Regarding current trading prices, SYRA is priced at $0.10, while IMACW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas IMACW's P/E ratio is N/A. In terms of profitability, SYRA's ROE is -1.28%, compared to IMACW's ROE of +2.46%. Regarding short-term risk, SYRA is less volatile compared to IMACW. This indicates potentially lower risk in terms of short-term price fluctuations for SYRA.
SYRA vs CCM Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, CCM has a market cap of 1.18M. Regarding current trading prices, SYRA is priced at $0.10, while CCM trades at $8.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas CCM's P/E ratio is -0.84. In terms of profitability, SYRA's ROE is -1.28%, compared to CCM's ROE of +0.13%. Regarding short-term risk, SYRA is more volatile compared to CCM. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs RHE-PA Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, RHE-PA has a market cap of 674535.00. Regarding current trading prices, SYRA is priced at $0.10, while RHE-PA trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas RHE-PA's P/E ratio is -0.09. In terms of profitability, SYRA's ROE is -1.28%, compared to RHE-PA's ROE of +2.66%. Regarding short-term risk, SYRA is less volatile compared to RHE-PA. This indicates potentially lower risk in terms of short-term price fluctuations for SYRA.
SYRA vs BACK Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, BACK has a market cap of 119605.00. Regarding current trading prices, SYRA is priced at $0.10, while BACK trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas BACK's P/E ratio is -0.01. In terms of profitability, SYRA's ROE is -1.28%, compared to BACK's ROE of +2.46%. Regarding short-term risk, SYRA is more volatile compared to BACK. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs NVOS Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, NVOS has a market cap of 23676.00. Regarding current trading prices, SYRA is priced at $0.10, while NVOS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas NVOS's P/E ratio is N/A. In terms of profitability, SYRA's ROE is -1.28%, compared to NVOS's ROE of -1.20%. Regarding short-term risk, SYRA is more volatile compared to NVOS. This indicates potentially higher risk in terms of short-term price fluctuations for SYRA.
SYRA vs NIVFW Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, NIVFW has a market cap of 1579.00. Regarding current trading prices, SYRA is priced at $0.10, while NIVFW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas NIVFW's P/E ratio is N/A. In terms of profitability, SYRA's ROE is -1.28%, compared to NIVFW's ROE of -0.39%. Regarding short-term risk, SYRA is less volatile compared to NIVFW. This indicates potentially lower risk in terms of short-term price fluctuations for SYRA.
SYRA vs IONM Comparison
SYRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRA stands at 1.19M. In comparison, IONM has a market cap of 313.00. Regarding current trading prices, SYRA is priced at $0.10, while IONM trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRA currently has a P/E ratio of -0.20, whereas IONM's P/E ratio is N/A. In terms of profitability, SYRA's ROE is -1.28%, compared to IONM's ROE of +0.75%. Regarding short-term risk, SYRA is less volatile compared to IONM. This indicates potentially lower risk in terms of short-term price fluctuations for SYRA.